Cardiff Oncology, Inc. (CRDF) Social Stream
CARDIFF ONCOLOGY INC (CRDF) Price Targets From Analysts
Use the tables below to see what analysts covering CARDIFF ONCOLOGY INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-24 | 4 | $26 | $25 | $25.333 | $1.57 | 1513.57% |
| 2021-12-08 | 5 | $26 | $19 | $23.75 | $1.57 | 1412.74% |
| 2022-01-19 | 6 | $26 | $19 | $23.75 | $1.57 | 1412.74% |
| 2022-02-27 | 6 | $26 | $19 | $22.75 | $1.57 | 1349.04% |
| 2022-04-12 | 6 | $25 | $19 | $22.5 | $1.57 | 1333.12% |
| 2022-05-06 | 6 | $25 | $9 | $18.25 | $1.57 | 1062.42% |
| 2022-05-09 | 6 | $22 | $9 | $17.5 | $1.57 | 1014.65% |
| 2022-05-10 | 6 | $22 | $9 | $15 | $1.57 | 855.41% |
| 2022-05-27 | 6 | $22 | $7 | $11.75 | $1.57 | 648.41% |
| 2022-08-08 | 5 | $22 | $7 | $12.666 | $1.57 | 706.75% |
| 2022-08-29 | 5 | $22 | $6 | $11.666 | $1.57 | 643.06% |
| 2022-09-13 | 5 | $22 | $5 | $11 | $1.57 | 600.64% |
| 2022-09-16 | 5 | $14 | $5 | $8.333 | $1.57 | 430.76% |
| 2023-05-05 | 5 | $15 | $5 | $8.333 | $1.57 | 430.76% |
| 2023-08-07 | 5 | $14 | $5 | $8 | $1.57 | 409.55% |
| 2023-08-08 | 5 | $13 | $5 | $7.666 | $1.57 | 388.28% |
| 2023-08-11 | 5 | $12 | $5 | $7.333 | $1.57 | 367.07% |
| 2023-11-07 | 5 | $12 | $5 | $8.5 | $1.57 | 441.4% |
The Trend in the Analyst Price Target
Over the past 22 months, CRDF's average price target has gone down $15.25.
CRDF reports an average of 408.84% for its upside potential over the past 36 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-03 | 5 | 14 | 5 | 8.000 | 1.76 | 354.55% |
| 2023-05-05 | 5 | 15 | 5 | 8.333 | 1.88 | 343.24% |
| 2023-08-08 | 5 | 13 | 5 | 7.666 | 2.18 | 251.65% |
| 2023-08-11 | 5 | 12 | 5 | 7.333 | 1.98 | 270.35% |
| 2023-11-07 | 5 | 12 | 5 | 8.500 | 1.09 | 679.82% |
CRDF Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 5 | 0 | 0 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
CRDF's average broker recommendation rating improved by 0 over the prior 22 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, CARDIFF ONCOLOGY INC's upside potential (average analyst target price relative to current price) is higher than 1818.5% of them.
- CARDIFF ONCOLOGY INC's variance in analysts' estimates is lower than -1265.71% of all US stocks.
- In the context of all US stocks, CARDIFF ONCOLOGY INC's average analyst price target is higher than 335.61% of them.
- In the context of Healthcare stocks, CARDIFF ONCOLOGY INC's number of analysts covering the stock is greater than 547.53% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to CARDIFF ONCOLOGY INC are CRIS, AIM, and MBOT.
View All Top Stocks by Price Target
What is the outlook for CRDF? Use POWR Ratings for clearer insight into price direction.